- Business
- EvoNext Holdings S.A. EvoNext Holdings SA (EVE.SW) operates as a holding company managing remaining assets following the divestment of its biotechnology operations. Incorporated in 2001 and headquartered in Reinach, Switzerland, the company previously focused on the discovery, research, development, and commercialization of nature-based ingredients for flavor and fragrances; health ingredients; health protection products; and other sectors, serving customers in Switzerland, the United States, and internationally through technology platforms combining biology and engineering as well as tailored technology services. It targets industries including novel food, nutritional, healthcare, and wellness segments with high-purity, sustainable ingredients produced via biotechnological processes.
In a major strategic shift, EvoNext Holdings S.A. sold its main operating subsidiary, Evolva AG, to a subsidiary of Lallemand Inc. in December 2023, transitioning from active biotechnology research to asset liquidation and management. Shareholders approved a name change from Evolva Holding SA to EvoNext Holdings SA in July 2025 at an extraordinary general meeting. The board continues to pursue mergers and acquisitions, including reverse takeovers and a public offer to acquire GZO AG that expired in July 2025, alongside publishing its half-year report for 2025 detailing ongoing M&A explorations.